Keywords: astrazeneca, zd6474, performs, well, phase, ii, trial
AstraZeneca's ZD6474 performs well in Phase II trial
Article | 30 May 2005
Anglo-Swedish drugmaker AstraZeneca reported positive results from trial 006 of its anticancer agent ZD6474 at the American Society of Clinical Oncology ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
